Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2013

01.10.2013 | Preclinical Study

Analysis of phyllodes tumor recurrence according to the histologic grade

verfasst von: Sewha Kim, Ji-Ye Kim, Do Hee Kim, Woo Hee Jung, Ja Seung Koo

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Local recurrence of phyllodes tumor (PT) of the breast is an adverse outcome that can result in sarcomatous degeneration. The aim of this study was to investigate the histologic and surgical factors associated with local recurrence. A total of 193 PT cases were studied: 145 (75.1 %) benign cases, 33 (17.1 %) borderline cases, and 15 (7.8 %) malignant cases. Stratifying our analysis according to histologic grade, we investigated the relationship between disease-free survival (DFS) and both histologic and surgical factors, including histologic grade, stromal cellularity, stromal atypia, stromal mitosis, stromal overgrowth, tumor margin, type of surgical procedure (local excision, wide excision, and mastectomy), surgical margin status, and radiation therapy. In the case of benign PT, all patients with local recurrences (3.4 %) had been treated with local excision, and all recurrent tumors were also benign. The local recurrence rate for locally excised benign PTs was not associated with surgical margin status or radiation therapy. In the case of borderline PT, local excision was associated with an increased local recurrence rate (P = 0.046). In malignant PT, small tumor size (≤4.0 cm) was associated with an increased local recurrence rate (P = 0.041). Univariate analyses indicated that surgical procedure (mastectomy < local excision < wide excision; P < 0.001) was significantly associated with shorter DFS in borderline PT. A positive surgical resection margin (P < 0.001) was associated with DFS in malignant PT. The factors associated with local recurrence differed with the histologic grade of PT, as did the features of local recurrence itself. In particular, benign PT had very low rate of local recurrence regardless of surgical margin status or radiation therapy, even when treated with local excision. In the case of benign PT, no recurrent tumors had worse histologic grades than the initial tumors.
Literatur
1.
Zurück zum Zitat Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van der Vijver MJ (2012) WHO classification of tumours of the breast. WHO, Geneva Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van der Vijver MJ (2012) WHO classification of tumours of the breast. WHO, Geneva
2.
Zurück zum Zitat Rosen PP (2009) Rosen’s breast pathology. Lippincott Williams and Wilkins, Philadelphia Rosen PP (2009) Rosen’s breast pathology. Lippincott Williams and Wilkins, Philadelphia
4.
Zurück zum Zitat Tan PH, Thike AA, Tan WJ, Thu MM, Busmanis I, Li H, Chay WY, Tan MH (2012) Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol 65:69–76. doi:10.1136/jclinpath-2011-200368 PubMedCrossRef Tan PH, Thike AA, Tan WJ, Thu MM, Busmanis I, Li H, Chay WY, Tan MH (2012) Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol 65:69–76. doi:10.​1136/​jclinpath-2011-200368 PubMedCrossRef
5.
Zurück zum Zitat Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, Susnik B, Giri D, Polo K, Patil S, Van Zee KJ (2007) Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol 14:2961–2970. doi:10.1245/s10434-007-9439-z PubMedCrossRef Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, Susnik B, Giri D, Polo K, Patil S, Van Zee KJ (2007) Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol 14:2961–2970. doi:10.​1245/​s10434-007-9439-z PubMedCrossRef
6.
Zurück zum Zitat Barth RJ Jr (1999) Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. Breast Cancer Res Treat 57:291–295PubMedCrossRef Barth RJ Jr (1999) Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. Breast Cancer Res Treat 57:291–295PubMedCrossRef
7.
Zurück zum Zitat Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL, Liu TP (2005) Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol 91:185–194. doi:10.1002/jso.20334 PubMedCrossRef Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL, Liu TP (2005) Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol 91:185–194. doi:10.​1002/​jso.​20334 PubMedCrossRef
9.
Zurück zum Zitat Kwon JE, Jung WH, Koo JS (2012) Molecules involved in epithelial-mesenchymal transition and epithelial-stromal interaction in phyllodes tumors: implications for histologic grade and prognosis. Tumour Biol 33:787–798. doi:10.1007/s13277-011-0296-9 PubMedCrossRef Kwon JE, Jung WH, Koo JS (2012) Molecules involved in epithelial-mesenchymal transition and epithelial-stromal interaction in phyllodes tumors: implications for histologic grade and prognosis. Tumour Biol 33:787–798. doi:10.​1007/​s13277-011-0296-9 PubMedCrossRef
10.
Zurück zum Zitat Pietruszka M, Barnes L (1978) Cystosarcoma phyllodes: a clinicopathologic analysis of 42 cases. Cancer 41:1974–1983PubMedCrossRef Pietruszka M, Barnes L (1978) Cystosarcoma phyllodes: a clinicopathologic analysis of 42 cases. Cancer 41:1974–1983PubMedCrossRef
11.
Zurück zum Zitat Salvadori B, Cusumano F, Del Bo R, Delledonne V, Grassi M, Rovini D, Saccozzi R, Andreola S, Clemente C (1989) Surgical treatment of phyllodes tumors of the breast. Cancer 63:2532–2536PubMedCrossRef Salvadori B, Cusumano F, Del Bo R, Delledonne V, Grassi M, Rovini D, Saccozzi R, Andreola S, Clemente C (1989) Surgical treatment of phyllodes tumors of the breast. Cancer 63:2532–2536PubMedCrossRef
12.
Zurück zum Zitat Hajdu SI, Espinosa MH, Robbins GF (1976) Recurrent cystosarcoma phyllodes: a clinicopathologic study of 32 cases. Cancer 38:1402–1406PubMedCrossRef Hajdu SI, Espinosa MH, Robbins GF (1976) Recurrent cystosarcoma phyllodes: a clinicopathologic study of 32 cases. Cancer 38:1402–1406PubMedCrossRef
13.
Zurück zum Zitat Zurrida S, Bartoli C, Galimberti V, Squicciarini P, Delledonne V, Veronesi P, Bono A, de Palo G, Salvadori B (1992) Which therapy for unexpected phyllode tumour of the breast? Eur J Cancer 28:654–657PubMedCrossRef Zurrida S, Bartoli C, Galimberti V, Squicciarini P, Delledonne V, Veronesi P, Bono A, de Palo G, Salvadori B (1992) Which therapy for unexpected phyllode tumour of the breast? Eur J Cancer 28:654–657PubMedCrossRef
14.
Zurück zum Zitat Chua CL, Thomas A, Ng BK (1989) Cystosarcoma phyllodes: a review of surgical options. Surgery 105:141–147PubMed Chua CL, Thomas A, Ng BK (1989) Cystosarcoma phyllodes: a review of surgical options. Surgery 105:141–147PubMed
15.
Zurück zum Zitat Moffat CJ, Pinder SE, Dixon AR, Elston CW, Blamey RW, Ellis IO (1995) Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology 27:205–218PubMedCrossRef Moffat CJ, Pinder SE, Dixon AR, Elston CW, Blamey RW, Ellis IO (1995) Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology 27:205–218PubMedCrossRef
16.
Zurück zum Zitat Tan PH, Jayabaskar T, Yip G, Tan Y, Hilmy M, Selvarajan S, Bay BH (2005) p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol 18:1527–1534. doi:10.1038/modpathol.3800488 PubMedCrossRef Tan PH, Jayabaskar T, Yip G, Tan Y, Hilmy M, Selvarajan S, Bay BH (2005) p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol 18:1527–1534. doi:10.​1038/​modpathol.​3800488 PubMedCrossRef
17.
Zurück zum Zitat Tse GM, Lui PC, Vong JS, Lau KM, Putti TC, Karim R, Scolyer RA, Lee CS, Yu AM, Ng DC, Tse AK, Tan PH (2009) Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors. Breast Cancer Res Treat 114:441–448. doi:10.1007/s10549-008-0030-5 PubMedCrossRef Tse GM, Lui PC, Vong JS, Lau KM, Putti TC, Karim R, Scolyer RA, Lee CS, Yu AM, Ng DC, Tse AK, Tan PH (2009) Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors. Breast Cancer Res Treat 114:441–448. doi:10.​1007/​s10549-008-0030-5 PubMedCrossRef
18.
Zurück zum Zitat Tse GM, Lui PC, Lee CS, Kung FY, Scolyer RA, Law BK, Lau TS, Karim R, Putti TC (2004) Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. Hum Pathol 35:1053–1057PubMedCrossRef Tse GM, Lui PC, Lee CS, Kung FY, Scolyer RA, Law BK, Lau TS, Karim R, Putti TC (2004) Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. Hum Pathol 35:1053–1057PubMedCrossRef
20.
Zurück zum Zitat Chong LY, Cheok PY, Tan WJ, Thike AA, Allen G, Ang MK, Ooi AS, Tan P, Teh BT, Tan PH (2012) Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification. Breast Cancer Res Treat 132:143–151. doi:10.1007/s10549-011-1555-6 PubMedCrossRef Chong LY, Cheok PY, Tan WJ, Thike AA, Allen G, Ang MK, Ooi AS, Tan P, Teh BT, Tan PH (2012) Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification. Breast Cancer Res Treat 132:143–151. doi:10.​1007/​s10549-011-1555-6 PubMedCrossRef
23.
Zurück zum Zitat Millar EK, Beretov J, Marr P, Sarris M, Clarke RA, Kearsley JH, Lee CS (1999) Malignant phyllodes tumours of the breast display increased stromal p53 protein expression. Histopathology 34:491–496PubMedCrossRef Millar EK, Beretov J, Marr P, Sarris M, Clarke RA, Kearsley JH, Lee CS (1999) Malignant phyllodes tumours of the breast display increased stromal p53 protein expression. Histopathology 34:491–496PubMedCrossRef
24.
Zurück zum Zitat Niezabitowski A, Lackowska B, Rys J, Kruczak A, Kowalska T, Mitus J, Reinfuss M, Markiewicz D (2001) Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: immunohistochemical and flow cytometric study of 118 cases. Breast Cancer Res Treat 65:77–85PubMedCrossRef Niezabitowski A, Lackowska B, Rys J, Kruczak A, Kowalska T, Mitus J, Reinfuss M, Markiewicz D (2001) Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: immunohistochemical and flow cytometric study of 118 cases. Breast Cancer Res Treat 65:77–85PubMedCrossRef
Metadaten
Titel
Analysis of phyllodes tumor recurrence according to the histologic grade
verfasst von
Sewha Kim
Ji-Ye Kim
Do Hee Kim
Woo Hee Jung
Ja Seung Koo
Publikationsdatum
01.10.2013
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2684-x

Weitere Artikel der Ausgabe 3/2013

Breast Cancer Research and Treatment 3/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.